MX388377B - Compuestos de indazol para usar en lesiones de tendones y/o ligamentos. - Google Patents

Compuestos de indazol para usar en lesiones de tendones y/o ligamentos.

Info

Publication number
MX388377B
MX388377B MX2019003362A MX2019003362A MX388377B MX 388377 B MX388377 B MX 388377B MX 2019003362 A MX2019003362 A MX 2019003362A MX 2019003362 A MX2019003362 A MX 2019003362A MX 388377 B MX388377 B MX 388377B
Authority
MX
Mexico
Prior art keywords
tendon
indazole compounds
ligament injuries
present
compounds
Prior art date
Application number
MX2019003362A
Other languages
English (en)
Other versions
MX2019003362A (es
Inventor
Andreas Fisch
Anne- Catherine REMOND
Badry Bursulaya
Eric Vangrevelinghe
Farshad RAMAZANI
Hank Michael James Petrassi
James Paul Lajiness
Peggy Usselmann
Rainer Machauer
Swapnil Malekar
Thomas Ullrich
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2019003362A publication Critical patent/MX2019003362A/es
Publication of MX388377B publication Critical patent/MX388377B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención proporciona un compuesto de fórmula (I) en forma libre o en forma de sal farmacéuticamente aceptable (ver Fórmula) un método para elaborar los compuestos de la invención, y sus usos terapéuticos. La presente invención además proporciona una combinación de agentes farmacológicamente activos y una composición farmacéutica.
MX2019003362A 2016-09-23 2017-09-21 Compuestos de indazol para usar en lesiones de tendones y/o ligamentos. MX388377B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662398869P 2016-09-23 2016-09-23
PCT/IB2017/055735 WO2018055550A1 (en) 2016-09-23 2017-09-21 Indazole compounds for use in tendon and/or ligament injuries

Publications (2)

Publication Number Publication Date
MX2019003362A MX2019003362A (es) 2019-07-04
MX388377B true MX388377B (es) 2025-03-19

Family

ID=60084023

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019003362A MX388377B (es) 2016-09-23 2017-09-21 Compuestos de indazol para usar en lesiones de tendones y/o ligamentos.

Country Status (36)

Country Link
US (1) US10112907B2 (es)
EP (1) EP3515894B1 (es)
JP (1) JP7007374B2 (es)
KR (1) KR102490953B1 (es)
CN (1) CN109715608B (es)
AR (1) AR109688A1 (es)
AU (1) AU2017332867B2 (es)
CL (1) CL2019000727A1 (es)
CO (1) CO2019002616A2 (es)
CR (1) CR20190145A (es)
CU (1) CU24553B1 (es)
CY (1) CY1124301T1 (es)
DK (1) DK3515894T3 (es)
DO (1) DOP2019000071A (es)
EA (1) EA038510B1 (es)
EC (1) ECSP19019589A (es)
ES (1) ES2878585T3 (es)
HR (1) HRP20211006T1 (es)
HU (1) HUE054910T2 (es)
IL (1) IL265066B (es)
JO (1) JOP20190054B1 (es)
LT (1) LT3515894T (es)
MX (1) MX388377B (es)
MY (1) MY196425A (es)
PE (1) PE20190657A1 (es)
PH (1) PH12019500327A1 (es)
PL (1) PL3515894T3 (es)
PT (1) PT3515894T (es)
RS (1) RS62145B1 (es)
RU (1) RU2749547C2 (es)
SG (1) SG11201901146SA (es)
SI (1) SI3515894T1 (es)
TW (1) TWI651308B (es)
UY (1) UY37412A (es)
WO (1) WO2018055550A1 (es)
ZA (1) ZA201900860B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190053A1 (ar) * 2016-09-23 2019-03-21 Novartis Ag مركبات أزا إندازول للاستخدام في إصابات الأوتار و/ أو الرباط
EP3908279B1 (en) 2019-01-11 2024-08-28 Novartis AG Lta4h inhibitor for the treatment or prevention of hidradenitis suppurativa
CA3235477A1 (en) * 2021-10-17 2023-04-20 Trigone Pharma Ltd. Compositions and methods for drug instillation into the urinary bladder
TW202342048A (zh) 2022-02-28 2023-11-01 瑞士商諾華公司 使用lou064治療化膿性汗腺炎之方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1343756A2 (en) * 2000-11-02 2003-09-17 Wyeth 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands
US7105532B2 (en) 2000-12-19 2006-09-12 Smithkline Beecham Corporation Pyrazolo[3,4-c]pyridines as gsk-3 inhibitors
WO2004078163A2 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
FR2871158A1 (fr) 2004-06-04 2005-12-09 Aventis Pharma Sa Indazoles substitues, compositions les contenant, procede de fabrication et utilisation
DE102004028862A1 (de) * 2004-06-15 2005-12-29 Merck Patent Gmbh 3-Aminoindazole
TW200616967A (en) 2004-06-24 2006-06-01 Smithkline Beecham Corp Novel indazole carboxamides and their use
FR2889526B1 (fr) 2005-08-04 2012-02-17 Aventis Pharma Sa 7-aza-indazoles substitues, compositions les contenant, procede de fabrication et utilisation
WO2008104473A2 (en) * 2007-02-28 2008-09-04 F. Hoffmann-La Roche Ag Pyrazolopyriidine derivatives and their use as kinase inhibitors
CN101790526A (zh) 2007-06-08 2010-07-28 雅培制药有限公司 用作激酶抑制剂的5-杂芳基取代的吲唑化合物
WO2010068287A2 (en) 2008-12-11 2010-06-17 Angion Biomedica Corp. Small molecule modulators of hepatocyte growth factor (scatter factor) activity
WO2011019780A1 (en) 2009-08-11 2011-02-17 Bristol-Myers Squibb Company Azaindazoles as btk kinase modulators and use thereof
JP2013542960A (ja) 2010-11-08 2013-11-28 グラクソスミスクライン、インテレクチュアル、プロパティー、ナンバー2、リミテッド 脂肪酸シンターゼ阻害剤
US9199979B2 (en) * 2011-02-24 2015-12-01 Nerviano Medical Sciences S.R.L. Thiazolylphenyl-benzenesulfonamido derivatives as kinase inhibitors
WO2012158810A1 (en) 2011-05-17 2012-11-22 Principia Biopharma Inc. Tyrosine kinase inhibitors
UA112028C2 (uk) * 2012-12-14 2016-07-11 Пфайзер Лімітед Похідні імідазопіридазину як модулятори гамка-рецептора
TWI629275B (zh) 2013-03-13 2018-07-11 賽諾菲公司 N-(4-(氮雜吲唑-6-基)-苯基)-磺醯胺及其作為醫藥之用途

Also Published As

Publication number Publication date
ECSP19019589A (es) 2019-03-29
AU2017332867B2 (en) 2020-03-05
BR112019005578A2 (pt) 2019-06-11
CU24553B1 (es) 2021-11-04
AR109688A1 (es) 2019-01-16
JP7007374B2 (ja) 2022-01-24
IL265066B (en) 2021-06-30
CU20190028A7 (es) 2019-11-04
DK3515894T3 (da) 2021-07-05
EP3515894B1 (en) 2021-04-07
CO2019002616A2 (es) 2019-06-11
PT3515894T (pt) 2021-07-13
HUE054910T2 (hu) 2021-10-28
WO2018055550A1 (en) 2018-03-29
ES2878585T3 (es) 2021-11-19
CR20190145A (es) 2019-06-03
HRP20211006T1 (hr) 2021-09-17
SG11201901146SA (en) 2019-04-29
PH12019500327A1 (en) 2019-11-11
UY37412A (es) 2018-04-30
JOP20190054A1 (ar) 2019-03-21
CN109715608B (zh) 2022-08-05
LT3515894T (lt) 2021-07-26
JOP20190054B1 (ar) 2023-03-28
JP2019529453A (ja) 2019-10-17
KR102490953B1 (ko) 2023-01-19
TWI651308B (zh) 2019-02-21
PE20190657A1 (es) 2019-05-08
PL3515894T3 (pl) 2021-10-25
RU2019111883A (ru) 2020-10-23
CN109715608A (zh) 2019-05-03
KR20190053223A (ko) 2019-05-17
TW201815767A (zh) 2018-05-01
RU2019111883A3 (es) 2020-11-05
US10112907B2 (en) 2018-10-30
CL2019000727A1 (es) 2019-05-17
EA038510B1 (ru) 2021-09-08
NZ751121A (en) 2025-03-28
ZA201900860B (en) 2021-06-30
DOP2019000071A (es) 2019-05-15
EA201990766A1 (ru) 2019-08-30
EP3515894A1 (en) 2019-07-31
RU2749547C2 (ru) 2021-06-15
RS62145B1 (sr) 2021-08-31
CA3033249A1 (en) 2018-03-29
CY1124301T1 (el) 2022-07-22
MY196425A (en) 2023-04-10
AU2017332867A1 (en) 2019-03-07
US20180086716A1 (en) 2018-03-29
SI3515894T1 (sl) 2021-08-31
MX2019003362A (es) 2019-07-04

Similar Documents

Publication Publication Date Title
PH12018501807A1 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of diseas
MX2015016344A (es) Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades.
MX388378B (es) Compuestos de aza-indazol para usar en lesiones de tendones y/o ligamentos.
MX2020011652A (es) Derivados de piridazina 1,4-disustituida, y su uso para el tratamiento de afecciones relacionadas con la deficiencia de smn.
EA201691058A1 (ru) Производные пирролопирролона и их применение для лечения заболеваний
CY1124251T1 (el) Παραγωγα καρβοξαμιδιου
MX2017012295A (es) Derivados formilados n-heterociclicos como inhibidores de fgfr4.
CY1124301T1 (el) Ενωσεις ινδαζολης για χρηση σε κακωσεις του τενοντα ή/και των συνδεσμων
EA201692298A1 (ru) Производные карбоксамидов
PH12016502247A1 (en) Carboxamide derivatives